Smyrna R&D Tax Credit Benefits for Your Business

R&D Tax Credits for Smyrna, Georgia Businesses

Smyrna, Georgia, boasts notable R&D companies like Glock, Coca-Cola Bottling Co., WellStar Health System, Lockheed Martin, and Cobb EMC. These organizations focus on defense, beverage technology, healthcare, and energy innovation. The R&D tax credit helps them reduce their tax liability by offsetting research expenses. This financial incentive enables them to reinvest in innovation, expand their research capabilities, and improve business performance, fostering economic growth and technological advancement in Smyrna.

Find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 400 West Peachtree Street NW, Atlanta, Georgia is less than 20 miles away from Smyrna and provides R&D tax credit consulting and advisory services to Smyrna and the surrounding areas such as: Atlanta, Sandy Springs, Roswell, Marietta and South Fulton.

If you have any questions or need further assistance, please call or email our local Georgia Partner on (404) 448-1354.
Feel free to book a quick teleconference with one of our Georgia R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Smyrna, Georgia Patent of the Year – 2024/2025

Geovax Inc. has been awarded the 2024/2025 Patent of the Year for its groundbreaking malaria vaccine innovation. Their invention, detailed in U.S. Patent No. 11857611, titled ‘Compositions and methods for generating an immune response to treat or prevent malaria’, the invention utilizes a modified vaccinia Ankara (MVA) vector to deliver Plasmodium antigens, aiming to both prevent and treat malaria.

This vaccine leverages GeoVax’s MVA platform to express malaria antigens within the body, prompting a robust immune response. Unlike traditional vaccines, this approach offers both prophylactic and therapeutic benefits, potentially transforming malaria management strategies.

Malaria remains a significant global health challenge, with millions affected annually. GeoVax’s innovative method addresses the urgent need for effective solutions. By inducing a strong immune response, the vaccine could reduce infection rates and aid in treating existing cases.

The patent’s issuance underscores the potential impact of this technology in combating malaria. As research progresses, GeoVax’s approach may play a crucial role in global health initiatives aimed at eradicating the disease.